Abstract
Chronic hepatitis B (CHB) is a serious global health concern, particularly in the Asia-Pacific region. New information on the clinical management of CHB is emerging rapidly, requiring that physicians be alerted to updated treatment recommendations. The ACT-HBV Asia-Pacific Steering Committee members, composed of experts in hepatitis B from throughout the Asia-Pacific region, reviewed and discussed new clinical data as reported in the literature or presented at recent international congresses, and recommended that physicians be alerted to updated treatment recommendations. Hepatitis B e antigen (HBeAg)-positive patients with HBV DNA levels of ≥20000IU/ml (≥105 copies/ml) and elevated alanine aminotransferase levels should be considered for treatment. It is suggested that HBV DNA≥2000IU/ml (≥104 copies/ml) is the more appropriate threshold for the treatment of HBeAg-negative patients. Lamivudine, adefovir dipivoxil, interferon α-2b, thymosin α-1, and, most recently, entecavir, and pegylated interferon α-2a are licensed for the management of CHB. The treatment recommendations from the 2005 Asian-Pacific Consensus Statement on the Management of Chronic Hepatitis B have been updated to incorporate these new therapeutic options. A summary of treatment recommendations for special patient populations is also included.
| Original language | English |
|---|---|
| Pages (from-to) | 47-58 |
| Number of pages | 12 |
| Journal | Liver International |
| Volume | 26 |
| Issue number | SUPPL. 2 |
| DOIs | |
| Publication status | Published - 2006 Dec 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hepatology
Cite this
}
Chronic hepatitis B : Treatment alert. / Chang, Ting-Tsung; Zhuang, Hua; Jia, Jidong; Leung, Nancy Wai Yee; Guan, Richard; Jafri, S. M.Wasim; Lesmana, Laurentius A.; Liaw, Yun Fan; Locarnini, Stephen; Omata, Masao; Sollano, Jose D.; Suh, Dong Jin; Mahachai, Varocha; Phiet, Pham Hoang; Sarin, Shiv K.; Yao, Guangbi; Yoon, Seung Kew.
In: Liver International, Vol. 26, No. SUPPL. 2, 01.12.2006, p. 47-58.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Chronic hepatitis B
T2 - Treatment alert
AU - Chang, Ting-Tsung
AU - Zhuang, Hua
AU - Jia, Jidong
AU - Leung, Nancy Wai Yee
AU - Guan, Richard
AU - Jafri, S. M.Wasim
AU - Lesmana, Laurentius A.
AU - Liaw, Yun Fan
AU - Locarnini, Stephen
AU - Omata, Masao
AU - Sollano, Jose D.
AU - Suh, Dong Jin
AU - Mahachai, Varocha
AU - Phiet, Pham Hoang
AU - Sarin, Shiv K.
AU - Yao, Guangbi
AU - Yoon, Seung Kew
PY - 2006/12/1
Y1 - 2006/12/1
N2 - Chronic hepatitis B (CHB) is a serious global health concern, particularly in the Asia-Pacific region. New information on the clinical management of CHB is emerging rapidly, requiring that physicians be alerted to updated treatment recommendations. The ACT-HBV Asia-Pacific Steering Committee members, composed of experts in hepatitis B from throughout the Asia-Pacific region, reviewed and discussed new clinical data as reported in the literature or presented at recent international congresses, and recommended that physicians be alerted to updated treatment recommendations. Hepatitis B e antigen (HBeAg)-positive patients with HBV DNA levels of ≥20000IU/ml (≥105 copies/ml) and elevated alanine aminotransferase levels should be considered for treatment. It is suggested that HBV DNA≥2000IU/ml (≥104 copies/ml) is the more appropriate threshold for the treatment of HBeAg-negative patients. Lamivudine, adefovir dipivoxil, interferon α-2b, thymosin α-1, and, most recently, entecavir, and pegylated interferon α-2a are licensed for the management of CHB. The treatment recommendations from the 2005 Asian-Pacific Consensus Statement on the Management of Chronic Hepatitis B have been updated to incorporate these new therapeutic options. A summary of treatment recommendations for special patient populations is also included.
AB - Chronic hepatitis B (CHB) is a serious global health concern, particularly in the Asia-Pacific region. New information on the clinical management of CHB is emerging rapidly, requiring that physicians be alerted to updated treatment recommendations. The ACT-HBV Asia-Pacific Steering Committee members, composed of experts in hepatitis B from throughout the Asia-Pacific region, reviewed and discussed new clinical data as reported in the literature or presented at recent international congresses, and recommended that physicians be alerted to updated treatment recommendations. Hepatitis B e antigen (HBeAg)-positive patients with HBV DNA levels of ≥20000IU/ml (≥105 copies/ml) and elevated alanine aminotransferase levels should be considered for treatment. It is suggested that HBV DNA≥2000IU/ml (≥104 copies/ml) is the more appropriate threshold for the treatment of HBeAg-negative patients. Lamivudine, adefovir dipivoxil, interferon α-2b, thymosin α-1, and, most recently, entecavir, and pegylated interferon α-2a are licensed for the management of CHB. The treatment recommendations from the 2005 Asian-Pacific Consensus Statement on the Management of Chronic Hepatitis B have been updated to incorporate these new therapeutic options. A summary of treatment recommendations for special patient populations is also included.
UR - http://www.scopus.com/inward/record.url?scp=33750701423&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750701423&partnerID=8YFLogxK
U2 - 10.1111/j.1478-3231.2006.01374.x
DO - 10.1111/j.1478-3231.2006.01374.x
M3 - Review article
AN - SCOPUS:33750701423
VL - 26
SP - 47
EP - 58
JO - Liver International
JF - Liver International
SN - 1478-3223
IS - SUPPL. 2
ER -